Zevenbergen Capital Investments LLC decreased its holdings in Nevro Corp. (NYSE:NVRO) by 3.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 618,735 shares of the medical equipment provider’s stock after selling 24,340 shares during the period. Nevro makes up approximately 2.4% of Zevenbergen Capital Investments LLC’s investment portfolio, making the stock its 15th largest position. Zevenbergen Capital Investments LLC owned about 2.09% of Nevro worth $56,231,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in NVRO. Ameritas Investment Partners Inc. boosted its position in Nevro by 17.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,432 shares of the medical equipment provider’s stock valued at $181,000 after buying an additional 358 shares during the period. PNC Financial Services Group Inc. purchased a new position in Nevro in the 2nd quarter valued at approximately $190,000. US Bancorp DE boosted its position in Nevro by 412.4% in the 2nd quarter. US Bancorp DE now owns 2,608 shares of the medical equipment provider’s stock valued at $194,000 after buying an additional 2,099 shares during the period. Los Angeles Capital Management & Equity Research Inc. purchased a new position in Nevro in the 3rd quarter valued at approximately $211,000. Finally, Prudential Financial Inc. lifted its position in shares of Nevro by 13.8% during the 2nd quarter. Prudential Financial Inc. now owns 2,878 shares of the medical equipment provider’s stock worth $214,000 after purchasing an additional 350 shares during the last quarter.
In related news, Director Michael F. Demane sold 5,000 shares of the firm’s stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $93.50, for a total transaction of $467,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Andrew H. Galligan sold 7,000 shares of the stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $75.11, for a total transaction of $525,770.00. The disclosure for this sale can be found here. Insiders have sold 63,467 shares of company stock worth $5,576,679 in the last three months. Insiders own 9.10% of the company’s stock.
Nevro Corp. (NYSE:NVRO) traded down $2.03 during mid-day trading on Wednesday, reaching $68.98. 848,100 shares of the company were exchanged, compared to its average volume of 508,562. Nevro Corp. has a 52-week low of $65.82 and a 52-week high of $99.63. The company has a current ratio of 8.78, a quick ratio of 6.81 and a debt-to-equity ratio of 0.59.
Nevro (NYSE:NVRO) last announced its quarterly earnings data on Monday, November 6th. The medical equipment provider reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.02. The business had revenue of $82.26 million for the quarter, compared to the consensus estimate of $80.50 million. Nevro had a negative net margin of 14.09% and a negative return on equity of 17.27%. The company’s quarterly revenue was up 35.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.14) earnings per share. equities analysts predict that Nevro Corp. will post -1.27 earnings per share for the current year.
Several equities research analysts have recently issued reports on NVRO shares. Morgan Stanley lifted their price objective on shares of Nevro from $87.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 8th. Northland Securities reissued a “buy” rating and issued a $96.00 price target on shares of Nevro in a research report on Tuesday, August 8th. Zacks Investment Research lowered shares of Nevro from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. BMO Capital Markets restated a “buy” rating and issued a $106.00 price objective on shares of Nevro in a research note on Friday, September 1st. Finally, BidaskClub upgraded shares of Nevro from a “sell” rating to a “hold” rating in a research note on Saturday, October 7th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. Nevro has an average rating of “Hold” and a consensus price target of $100.00.
TRADEMARK VIOLATION WARNING: This piece was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://ledgergazette.com/2017/12/06/nevro-corp-nvro-position-reduced-by-zevenbergen-capital-investments-llc.html.
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.